Novel antiplatelet drugs in clinical development

The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold prom...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 110; no. 5; p. 868
Main Authors Ungerer, M, Münch, G
Format Journal Article
LanguageEnglish
Published Germany 01.11.2013
Subjects
Animals
Cerebrovascular Disorders - drug therapy
Clinical Trials as Topic
Drug Discovery
Humans
Platelet Aggregation Inhibitors - pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Purinergic P2Y Receptor Antagonists - therapeutic use
Receptor, PAR-1 - antagonists & inhibitors
Risk Assessment
Online AccessGet more information

Cover

More Information
Summary:The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.
ISSN:0340-6245
DOI:10.1160/TH13-02-0084